Dose-Dependent Interaction of Paroxetine With Risperidone in Schizophrenic Patients

Manabu Saito, MD, Norio Yasui-Furukori, MD, PhD, Taku Nakagami, MD, Hanako Furukori, MD, PhD, and Sunao Kaneko, MD, PhD

Abstract: Augmentation with paroxetine (10–40 mg/d) for antipsychotic treatment may improve the negative symptoms in schizophrenic patients but involves a risk of drug-drug interaction. We studied the effects of paroxetine on plasma concentrations of risperidone and 9-hydroxyrisperidone and their clinical symptoms in risperidone-treated patients. Twelve schizophrenic inpatients with prevailingly negative symptoms receiving risperidone 4 mg/d were, in addition, treated with incremental doses of paroxetine for 12 weeks (10, 20, and 40 mg/d for 4 weeks each). Plasma concentrations of risperidone and 9-hydroxyrisperidone were quantified with liquid chromatography–mass spectrometry mass-mass spectrometry together with clinical assessments before and after each phase of the 3 paroxetine doses. Risperidone concentrations during coadministration of paroxetine 10, 20, and 40 mg/d were 3.8-fold (95% confidence interval, 3.2–5.8, $P < 0.01$), 7.1-fold (95% confidence interval, 5.3–16.5, $P < 0.01$), and 9.7-fold (95% confidence interval, 7.8–22.5, $P < 0.01$) higher than that before paroxetine coadministration, respectively. Active moiety (risperidone plus 9-hydroxyrisperidone) concentration was not increased during the paroxetine 10 mg/d (1.3-fold, not significant) or 20 mg/d (1.6-fold, not significant), but were significantly increased by 1.8-fold (95% confidence interval, 1.4–2.7, $P < 0.05$) during the paroxetine 40 mg/d. Significant improvement in negative symptoms was observed from 10 to 40 mg/d of paroxetine, whereas scores in extrapyramidal side effects during 20 and 40 mg/d of paroxetine were significantly higher than baseline score. This study indicates that paroxetine increases plasma risperidone concentration and active moiety concentration in a dose-dependent manner. Low-dose coadministration of paroxetine with risperidone may be safe and effective in the treatment of schizophrenic patients with negative symptoms.

(*J Clin Psychopharmacol* 2005;25:527–532)

Negative symptoms play an important role in schizophrenia and are related to deficits in global functioning and global outcome. The atypical neuroleptics have proven to be effective in treating negative symptoms. However, although clinical experience appears to show that they have advantages over the traditional neuroleptics in treating negative symptoms, superiority has not always been statistically confirmed, and the treatment results in individual patients in everyday clinical practice are often not satisfying.[1] Therefore, other drug treatment options also have to be carefully considered.

Although the role and mechanism of antidepressant drugs as an adjunct in the treatment of schizophrenic patient with negative symptoms remain unclear, there is some evidence that adding an antidepressant that is a selective serotonin reuptake inhibitor to antipsychotic agents improves negative symptoms of schizophrenia.[2] However, a problem is the risk of possible pharmacodynamic and/or pharmacokinetic interactions when using antidepressants as an adjunctive therapy. Particularly, the pharmacokinetic consequences of combination of selective serotonin reuptake inhibitors and neuroleptics should be carefully considered. The selective serotonin reuptake inhibitors differ substantially in their potential for pharmacokinetic drug interactions, which reflects a difference in their effect on cytochrome P450 isoenzymes (CYP) in the liver.[3]

Risperidone is an atypical antipsychotic with a potent serotonin 5-HT_2 and a moderate dopamine D_2 antagonistic activity.[4] It is effective in the treatment of both positive and negative symptoms of schizophrenia and has a lower potential to cause extrapyramidal symptoms, compared with classic antipsychotic agents.[5] Risperidone is metabolized in the liver by CYP, mainly by 9-hydroxylation and, to a lesser extent, by *N*-dealkylation and 7-hydoxylation.[6] Several in vitro studies with human liver microsomes and recombinantly expressed microsomes have demonstrated that the formation of 9-hydroxyrisperidone is predominantly catalyzed by CYP2D6 and, to a lesser extent, CYP3A4.[7,8] Furthermore, several in vivo studies have shown that the steady-state plasma concentration of risperidone is increased with the number of mutated alleles for CYP2D6 in schizophrenic patients.[9–12] Thus, CYP2D6 is predominantly involved in the risperidone metabolism.

Augmentation of paroxetine to risperidone is relatively common and proposed for the treatment of negative symptoms of schizophrenia and other psychiatric disease, for example, major depression or obsessive-compulsive disease.[13,14] Spina et al[15] suggest that a significant pharmacokinetic interaction of this combination occurs through CYP2D6 inhibition. However, there is no information about therapeutic and toxic dose of paroxetine when added to risperidone.

Therefore, this study was designed to investigate the dose effects of paroxetine on the steady-state plasma

Department of Neuropsychiatry Hirosaki University School of Medicine, Hirosaki, Japan.
Received January 3, 2005; accepted after revision June 20, 2005.
Address correspondence and reprint requests to Norio Yasui-Furukori, MD, PhD, Department of Neuropsychiatry, Hirosaki University, School of Medicine, Hirosaki 036-8562, Japan. E-mail: yasufuru@cc.hirosaki-u.ac.jp.

ISSN: 0271-0749/05/2506-0527
DOI: 10.1097/01.jcp.0000185428.02430.c7

concentrations of risperidone, 9-hydroxyrisperidone, and active moiety during incremental doses of paroxetine. Moreover, changes in psychiatric symptoms and neuroleptic side effects occurring contemporaneously with concomitant administration of paroxetine were evaluated.

MATERIAL AND METHODS

Subjects

Twelve Japanese schizophrenic inpatients (7 women and 5 men), who fulfilled the criteria for schizophrenia, according to the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* and had negative symptoms in spite of undergoing risperidone therapy and required selective serotonin reuptake inhibitor therapy, were selected for the study. The mean ± SD of age was 52.3 ± 10.3 years (range, 33–67), body weight was 67.6 ± 8.2 kg (range, 57–83), and duration of illness was 298.8 ± 110.9 months (range, 84–482). The study was approved by the ethics committee of Hirosaki University Hospital, and written informed consent to participate in this study was obtained from the patients and their families.

Protocol

Before paroxetine coadministration, subjects had been treated for at least 6 weeks (range, 6–156) with fixed dose of risperidone. Dose of risperidone was 4 mg/d, and frequency was twice daily (8 am and 8 pm). The elimination half-lives of risperidone and 9-hydroxyrisperidone were reported to be 3 to 20 hours and 20 to 29 hours, respectively. Therefore, plasma concentrations of these compounds already reached steady state in all subjects before initiating the study. Dosage and frequency of administration of risperidone were fixed throughout the duration of the study. Paroxetine 10 mg once a day (8 pm) was coadministered to all the subjects for the first 4 weeks, followed by 20 mg/d for the next 4 weeks, and finally, 40 mg/d for the last 4 weeks. Concomitant treatment with other medications, flunitrazepam (1–3 mg/d) in 6 patients, nitrazepam (10 mg/d) in 1 patient, brotizolam (0.5 mg/d) in 1 patient, etizolam (2–6 mg/d) in 2 patients, zolpidem (7.5 mg/d) in 1 patient, sennoside (12–24 mg/d) in 3 patients, etilefrine hydrochloride (15–20 mg/d) in 2 patients, amezinium metilsulfate (20 mg/d) in 3 patients, atorvastatin calcium hydrate (20 mg/d), and benidipine hydrochloride (8 mg/d) in 1 patient, was also fixed throughout the study period. None of the subjects received drugs known as inhibitors or inducer of CYP2D6 or 3A4 in risperidone metabolism.[16]

Plasma sample collections were performed before and 4 weeks after each dose sequence of 10, 20, and 40 mg/d of paroxetine coadministration. Sampling for pharmacokinetics determination was drawn at 8 am (approximately 12 hours after the last dose of risperidone and the paroxetine dose and before the morning dose of risperidone).

On the same days as the blood samplings, psychiatric symptoms and side effects were evaluated by Positive and Negative Syndrome Scale (PANSS),[17] the Calgary Depression Scale for Schizophrenics (CDSS),[18] and the Udvalg for Kliniske Undersøgelser (UKU) side effects rating scale,[19] respectively. Patients were evaluated by the same investigator. This investigator from other hospital was not involved in the study patient care and was blind to drug regimens and result of drug concentrations. However, he had access to the nursing charts.

Each of the 30 items of the PANSS was assessed by 7-scale steps from 1 (not present) to 7 (extremely severe). The 25 items were divided into 5 clusters: negative (emotional withdrawal, passive/apathetic withdrawal, lack of spontaneity, poor rapport, blunted affect, and active social avoidance), excitement (excitement, poor impulse control, hostility, and tension), cognitive (conceptual disorganization, disorientation, difficulty in abstract thinking, mannerisms and posturing, and poor attention), positive (delusions, unusual thought content, grandiosity, suspiciousness/persecution, and hallucinations), and depression (anxiety, guilt feelings, depression, somatic concern, and preoccupation) symptoms as classified by Lindenmayer et al.[20] Nine items of the Japanese version of the CDSS, which was a depression scale for schizophrenia patients, were assessed by total scores. Nineteen items were selected from the UKU side effects rating scale to assess the side effects of risperidone, which were divided into 3 subgroups: psychic (concentration difficulties, asthenia, sleepiness, failing memory, depression, and tension), extrapyramidal (dystonia, rigidity, hypokinesia, hyperkinesias, tremor, akathisia, and increased salvation), and autonomic (accommodation disturbances, reduced salvation, constipation, micturition disturbances, orthostatic dizziness, and palpitation) side effects.

Assay

Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured using the liquid chromatography–mass spectrometry mass-mass spectrometry method. The extraction procedure was as follows: 200 μL of 0.1 mol/L phosphate buffer (pH 7), 50 μL internal standard (R068808, Janssen Research Foundation, Beerse, Belgium), and 100 μL methanol were added, and after this, 400 μL of 0.1 mol/L borax was added. The mixture was vortexed and poured over an Extrelut NT 1 (Merck, Boston, Massachusetts) column, which was eluted with 7 mL ethyl acetate. The eluate was evaporated under a nitrogen stream at 65°C. The residues were redissolved in 200 μL acetonitrile/0.01 mol/L ammonium acetate (50/50, pH 9.0), and 5 μL was injected onto the liquid chromatography–mass spectrometry mass-mass spectrometry system. The system consisted of API 3000 (Sceix) and a column (Hypersil BDS C18, 100 × 4.6 mm, 3-μm particle size, Chemco Scientific, Brussels, Belgium). The mobile phase was an ammonium acetate (0.01 mol/L, pH 9.0)–acetonitrile gradient. Among the fragment ions of the compounds, the mass-to-ratio (m/z) 207.0 for risperidone, m/z 191.0 for 9-hydroxyrisperidone, and m/z 201.0 for the internal standard were selected for ion monitoring. The lower limit of detection was 0.1 ng/mL, and the values of the interassay coefficient of variation were less than 5% at all the concentrations of calibration curves for risperidone and 9-hydroxyrisperidone.

The *CYP2D6*1* (**1*), *CYP2D6*3*, and *CYP2D6*4* alleles were identified by allele-specific polymerase chain reaction

analysis according to Heim and Meyer.[21] A long–polymerase chain reaction analysis was used to detect the *CYP2D6*5* (**5*) allele.[22] The *CYP2D6*10* (**10*) allele was identified as the *C188T* mutation using a 2-step polymerase chain reaction analysis as described by Johansson et al.[23] The *CYP2D6*14* (**14*) allele was identified as the *G1846T/A* mutation using a 2-step polymerase chain reaction analysis as described by Kubota et al.[24] The *CYP2D6*2* does not result in decreased CYP2D6 activity. Therefore, the *CYP2D6*2* was regarded as the wild-type (wt) allele, together with the *CYP2D6*1*.

Statistical Analyses

The repeated measurement of analysis of variance followed by Bonferroni correction and Friedman test followed by Bonferroni correction were used for the comparison of the plasma drug concentrations and scores of clinical assessments, respectively, among 4 phases, that is, before and during paroxetine coadministration at 10, 20, and 40 mg/d. Correlations between the changes in plasma concentrations of risperidone, 9-hydroxyrisperidone, and active moiety were tested using linear regression analysis. A P value of 0.05 or less was regarded as significant. SPSS 12.0 for Windows (SPSS Japan Inc, Tokyo, Japan) was used for these statistical analyses.

RESULTS

Plasma concentrations of risperidone and 9-hydroxyrisperidone, active moiety, and metabolic ratio (risperidone/9-hydroxyrisperidone) before and during paroxetine coadministration are summarized in Table 1. Mean plasma concentrations of risperidone during coadministration of paroxetine 10, 20, and 40 mg/d were 3.8-fold (95% confidence interval [CI], 3.2–5.8, $P < 0.01$), 7.1-fold (95% CI, 5.3–16.5, $P < 0.01$), and 9.7-fold (95% CI, 7.8–22.5, $P < 0.01$) significantly higher than those before paroxetine coadministration. No significant change was found in 9-hydroxyrisperidone concentrations between baseline and coadministration of paroxetine 10 mg/d (0.9-fold), 20 mg/d (0.9-fold), and 40 mg/d (0.8-fold). Active moiety was not increased during the paroxetine 10 mg/d (1.3-fold, not significant) or 20 mg/d (1.6-fold, not significant), but was significantly increased by 1.8-fold (95% CI, 1.4–2.7, $P < 0.05$) during the paroxetine 40 mg/d. Metabolic ratio increased significantly during coadministration of paroxetine 10 mg/d by 4.2-fold (95% CI, 3.4–6.2, $P < 0.001$), 20 mg/d by 8.2-fold (95% CI, 6.0–16.0, $P < 0.001$), and 40 mg/d by 12.6-fold (95% CI, 9.6–26.8, $P < 0.001$).

Five *CYP2D6* genotypes were identified in the patients: 2 heterozygotes of the **1* and **2* alleles, 6 heterozygotes of the **1* and **10*, 1 heterozygote of the **2* and **10*, 2 homozygotes of the **10*, and 1 heterozygote of **5* and **10*. These patients were divided into 3 groups according to the number of mutated alleles: 0 mutated allele in 2 patients, 1 mutated allele in 7 patients, and 2 mutated alleles in 3 patients. Large differences in the percentage of control in risperidone concentration and baseline ratios with paroxetine coadministration were observed between *CYP2D6* genotype groups. They had smaller change in risperidone concentration during paroxetine coadministration, although it was not statistically significant because of small number of subjects. There were significant correlations in paroxetine-mediated increase in plasma concentration of risperidone during 10 mg/d ($r_s = -0.671$, $P < 0.05$), 20 mg/d ($r_s = -0.804$, $P < 0.01$), and 40 mg/d ($r_s = -0.832$, $P < 0.001$) (Fig. 1).

Scores of negative symptoms were significantly reduced after coadministration of paroxetine 10 mg ($P < 0.05$), 20 mg ($P < 0.01$), and 40 mg ($P < 0.01$), respectively, whereas those in total PANSS, excitement, cognitive, positive, and depression symptoms were unchanged (Table 2). No changes were found in scores of total CDSS throughout the study. Scores in UKU side effects rating scale were increased significantly in total by paroxetine 40 mg

TABLE 1. Changes in Drug Concentrations, Before and After Coadministration With Incremental Doses of Paroxetine in 12 Schizophrenic Patients

	Paroxetine Dose (mg/d)			
	0	10	20	40
Risperidone (ng/mL)	10.4 ± 18.5	25.9 ± 24.7*	41.9 ± 29.4*	58.5 ± 41.7*
Ratio to baseline		3.8 (3.2, 5.8)	7.1 (5.3, 16.5)	9.7 (7.8, 22.5)
9-OH risperidone (ng/mL)	38.0 ± 18.2	35.1 ± 15.5	33.6 ± 15.5	32.6 ± 23.7
Ratio to baseline		0.9 (0.8, 1.0)	0.9 (0.6, 2.1)	0.8 (0.5, 2.0)
Active moiety (ng/mL)	48.4 ± 35.2	61.0 ± 37.2	75.5 ± 43.8	91.1 ± 64.3†
Ratio to baseline		1.3 (1.2, 1.5)	1.6 (1.2, 2.3)	1.8 (1.4, 2.7)
Metabolic Ratio	0.2 ± 0.2	0.7 ± 0.5‡	1.2 ± 0.4‡	1.8 ± 0.4‡
Ratio to baseline		4.2 (3.4, 6.2)	8.2 (6.0, 16.0)	12.6 (9.6, 26.8)
Paroxetine (ng/mL)	—	11.0 ± 12.8	45.0 ± 42.4	189.3 ± 138.5

Drug concentrations are shown as mean ± SD (range). Ratio to baseline are shown as geometric mean (95% CI). 9-OH risperidone indicates 9-hydroxyrisperidone; active moiety, risperidone plus 9-OH risperidone; metabolic ratio, risperidone/9-OH risperidone.

*$P < 0.01$, compared with baseline and obtained by Bonferroni multiple comparison.

†$P < 0.05$, compared with baseline and obtained by Bonferroni multiple comparison.

‡$P < 0.001$, compared with baseline and obtained by Bonferroni multiple comparison.



FIGURE 1. Correlations between baseline concentration ratio of 9-hydroxyrisperidone to risperidone and the magnitude of paroxetine-mediated increase in risperidone concentration in schizophrenic patients receiving 4 mg/d of risperidone. Open circles indicate data of patients with no mutated allele for CYP2D6. Open squares and triangles indicate data of patients with 1 and 2 mutated alleles for CYP2D6, respectively.

coadministration ($P < 0.05$) and in extrapyramidal symptoms by 20 mg ($P < 0.05$) and 40 mg ($P < 0.05$), whereas there were no significant differences in psychic and autonomic symptoms.

DISCUSSION

The results of this study showed that coadministration of paroxetine resulted in significant increase in the plasma concentration of risperidone, which is in line with previous in vivo interaction studies with paroxetine,[8] fluoxetine,[25] and thioridazine.[26] Plasma concentrations of risperidone during coadministration of paroxetine 10, 20, and 40 mg/d were increased by 3.8-fold, 7.1-fold, and 9.7-fold, respectively, suggesting that the interaction between paroxetine and risperidone occurs in a dose-dependent manner. In addition, metabolic ratio increased significantly during coadministration of paroxetine 10 mg/d by 4.2-fold, 20 mg/d by 8.2-fold, and 40 mg/d by 12.6-fold. Thus, this finding implies that CYP2D6 catalyzing 9-hydroxylation plays important role in this interaction. Surprisingly, only even 10 mg/d of paroxetine has a potent inhibitory effect on risperidone metabolism. Therefore, careful monitoring is required even when low dose of paroxetine is added to neuroleptics catalyzed by CYP2D6, such as perphenazine, thioridazine, and zuclopenthixol.

TABLE 2. Changes in PANSS, CDSS, and UKU Scores Before and After Coadministration With Incremental Doses of Paroxetine in 12 Schizophrenic Patients

	Paroxetine Dose (mg/d)			
	0	10	20	40
PANSS scores				
Total	72.2 ± 14.6	67.4 ± 16.6	60.0 ± 10.0	64.9 ± 13.3
Negative	24.9 ± 3.7	18.9 ± 6.0*	17.2 ± 5.9†	18.8 ± 4.1†
Excitement	8.0 ± 1.5	8.3 ± 2.3	8.1 ± 1.6	8.7 ± 2.5
Cognitive	13.6 ± 4.2	13.3 ± 5.2	11.5 ± 2.2	13.6 ± 4.1
Positive	13.0 ± 4.4	13.6 ± 4.6	12.5 ± 3.1	12.5 ± 2.7
Depression	12.7 ± 5.0	13.3 ± 4.6	10.8 ± 2.9	11.3 ± 4.4
CDSS scores				
Total	3.4 ± 2.1	2.9 ± 2.6	2.3 ± 2.1	1.9 ± 2.1
UKU scores				
Total	3.2 ± 2.5	3.4 ± 3.1	4.7 ± 3.3	6.3 ± 4.6*
Psychic	1.5 ± 1.6	1.3 ± 1.7	1.6 ± 1.6	2.5 ± 2.2
Extrapyramidal	0.5 ± 0.8	1.0 ± 1.2	1.8 ± 1.9*	2.3 ± 2.7*
Autonomic	1.2 ± 1.2	1.1 ± 1.4	1.3 ± 1.5	1.4 ± 1.9

Data are shown as mean ± SD.
*$P < 0.05$, compared with baseline and obtained by Bonferroni multiple comparison.
†$P < 0.01$, compared with baseline and obtained by Bonferroni multiple comparison.

As with risperidone, paroxetine metabolism is primarily involved in mediation by CYP2D6 in the liver,[27] whereas several in vitro studies have shown that paroxetine is an inhibitor of CYP2D6.[27–30] An in vivo study has shown that 83% of subjects phenocopied to PM status after receiving the paroxetine 20 mg/d, as measured by dextromethorphan/dextrorphan urinary ratio.[31] Jeppesen et al[32] have demonstrated that CYP2D6 activity was proportionately decreased with incremental dose of paroxetine, and 3 of the 6 volunteers changed phenotype from extensive metabolizers to poor metabolizers after only a single oral dose of 40 or 80 mg paroxetine, as measured by sparteine. Moreover, paroxetine 20 mg daily resulted in a change in all individuals from ultrarapid metabolizers to normal extensive metabolizers, as measured by debrisoquine metabolic ratio, and the high paroxetine concentrations in 2 subjects treated with 40 mg daily caused them to be poor metabolizers.[33] In addition, a recent in vitro study with human liver microsome demonstrated that paroxetine exhibited a preincubation-dependent increase in inhibitory potency, suggesting mechanism-based inhibition of CYP2D6 by paroxetine.[34] Based on these findings, therefore, the inhibitory effect of paroxetine on CYP2D6 activity is potent and occurs in a dose-dependent manner, which supports our findings.

No change was found in 9-hydroxyrisperidone throughout the study period. This finding was also obtained in previous other studies with paroxetine[8] and fluoxetine.[25] Although we do not have clear explanation for it, paroxetine might inhibit the further elimination of 9-hydroxyrisperidone because paroxetine affects other metabolic pathways of risperidone such as 7-hydroxylation and *N*-dealkylation or both.

There were significant correlations between paroxetine-mediated increase in risperidone concentration during each phase of paroxetine coadministration and baseline metabolic ratio of risperidone/9-hydroxyrisperidone that is regarded as index of CYP2D6 activity. Moreover, *CYP2D6* genotype was linked with the baseline metabolic ratio of risperidone/9-hydroxyrisperidone. This is not a surprising finding because patients with mutated alleles have low activity of CYP2D6, which paroxetine is expected to inhibit. Thus, the magnitude of this drug interaction can be predicted by CYP2D6 activity.

However, another mechanism should also be considered. Recently, an in vitro study has shown that quetiapine and risperidone have stronger affinity to P-glycoprotein than other atypical antipsychotic drugs, suggesting that quetiapine and risperidone are substrates of P-glycoprotein,[35] while an in vitro study with cell lines has recently demonstrated that the inhibitory effect of paroxetine on P-glycoprotein is potent.[36] In addition, a population-based, nested, case-control study suggested an increased risk of toxicity of digoxin, which is a substrate of P-glycoprotein,[37] after initiation of paroxetine (odds ratio, 2.8; 95% CI, 1.6–4.7).[38] Therefore, the bioavailability of risperidone might, to some extent, be increased through inhibition of risperidone transporting back to the intestinal lumen after absorption by paroxetine treatment, although the contribution of P-glycoprotein to risperidone disposition and inhibitory effect of paroxetine on P-glycoprotein are under further in vivo investigation.

Although interpretation of pharmacodynamic results must be limited because double-blind methodology was not conducted in the present study, it is noteworthy that significant changes in clinical symptoms or side effects were observed during paroxetine coadministration (Table 2). Improvement of negative symptoms observed during the administration of paroxetine from 10 to 40 mg/d in this study suggests that an activating effect of augmentation of risperidone on chronic patients occurs even with a low dose of paroxetine. Coadministration of 20 and 40 mg/d of paroxetine led to worsening of extrapyramidal side effects probably because of elevation in active moiety concentration. This interaction may have clinical implication leading to potentially toxic total plasma risperidone levels. Careful clinical observation and monitoring of plasma risperidone levels may be useful whenever paroxetine is coadministered with risperidone, and low doses of paroxetine should be recommended for augmentation therapy. If no improvement of negative symptoms is observed, carefully monitored titration of paroxetine is required.

In trials using antidepressants for the treatments of depressive symptoms or negative symptoms in schizophrenia, it has been described that the improvement of the positive symptoms might be delayed and/or that a relapse of positive symptoms can occur in patients who already had a partial full remission of psychotic symptoms.[39,40] In fact, our previous study reported that 3 of 12 patients had a worsening of excitement symptoms after adding fluvoxamine to haloperidol.[41] However, no relapse in any patients was observed throughout the study period. The increased plasma concentration of active moiety might be attributed to avoidance of this kind of risk, although extrapyramidal side effects increased.

In conclusion, paroxetine increases plasma concentrations of risperidone and active moiety in a dose-dependent manner. This drug interaction may be explained by an inhibitory effect of CYP2D6 activity proportionately with paroxetine doses. Low-dose coadministration of paroxetine with risperidone may be safe and effective in the treatment of schizophrenic patients with negative symptoms.

ACKNOWLEDGMENT

This study was supported by a grant from the Hirosaki Research Institute for Neurosciences and by an advanced medical development cost (B) from Japanese Ministry of Education, Culture, Sports and Technology and a strategic cost from Hirosaki University. The authors and their institutes have no conflicts of interest.

REFERENCES

1. Moller HJ. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2004;254:108–116.
2. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. *CNS Drug Rev*. 2001;7:283–304.
3. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Drug interactions with newer antidepressants: role of human cytochromes P450. *J Clin Psychiatry*. 1998;59(suppl 15):19–27.

4. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. *J Pharmacol Exp Ther.* 1988;247:661–670.
5. Chouinard G, Arnott W. Clinical review of risperidone. *Can J Psychiatry.* 1993;38(suppl 3):S89–95.
6. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. *Drug Metab Dispos.* 1993;21:1134–1141.
7. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. *Naunyn Schmiedebergs Arch Pharmacol.* 1999;359:147–151.
8. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. *Drug Metab Dispos.* 2001;29:1263–1368.
9. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. *Psychopharmacology (Berl).* 1999;147:300–305.
10. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to *CYP2D6*10* allele in Korean schizophrenic patients. *Eur J Clin Pharmacol.* 2001;57:671–675.
11. Yasui-Furukori N, Mihara K, Kondo T, et al. Effects of *CYP2D6* genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. *J Clin Pharmacol.* 2003;43:122–127.
12. Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various *CYP2D6* genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. *Ther Drug Monit.* 2003;25:287–293.
13. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. *J Clin Psychiatry.* 1999;60:256–259.
14. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor–refractory obsessive-compulsive disorder. *Arch Gen Psychiatry.* 2000;57:794–801.
15. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. *Ther Drug Monit.* 2001;23:223–227.
16. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. *J Clin Psychiatry.* 1999;60:469–476.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull.* 1987;13:261–276.
18. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. *Schizophr Res.* 1996;19:205–212.
19. Lingjærde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatr Scand Suppl.* 1987;334:1–100.
20. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a 5-factor model. *Psychopathology.* 1995;28:22–31.
21. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. *Lancet.* 1990;336:529–532.
22. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated *CYP2D6(D)* gene deletion allele by long-PCR technology. *Pharmacogenetics.* 1995;5:215–223.
23. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant *CYP2D6* genes present in subjects with diminished capacity for debrisoquine hydroxylation. *Mol Pharmacol.* 1994;46:452–459.
24. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of *CYP2D6* mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan *O*-demethylation in different *CYP2D6* genotypes. *Br J Clin Pharmacol.* 2000;50:31–34.
25. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. *J Clin Psychopharmacol.* 2002;22:419–423.
26. Nakagami T, Yasui-Furukori N, Saito M, et al. Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction. *J Clin Psychopharmacol.* 2005;25:89–91.
27. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. *Br J Clin Pharmacol.* 1992;33:521–523.
28. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. *Br J Clin Pharmacol.* 1992;34:256–261.
29. Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. *Pharmacol Exp Ther.* 1996;277:1659–1664.
30. Ball SE, Ahern D, Scatina J, et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. *Br J Clin Pharmacol.* 1997;43:619–626.
31. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. *J Clin Pharmacol.* 2000;40:58–66.
32. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. *Eur J Clin Pharmacol.* 1996;51:73–78.
33. Laine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquine test. *Clin Pharmacol Ther.* 2001;70:327–335.
34. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. *Drug Metab Dispos.* 2003;31:289–293.
35. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. *Life Sci.* 2002;71:163–169.
36. Weiss J, Kerpen CJ, Lindenmaier H, et al. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. *J Pharmacol Exp Ther.* 2003;307:262–267.
37. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). *J Pharmacol Exp Ther.* November 1992;263(2):840–845.
38. Juurlink DN, Mamdani MM, Kopp A, et al. A population-based assessment of the potential interaction between serotonin specific reuptake inhibitors and digoxin. *Br J Clin Pharmacol.* 2005;59:102–107.
39. Prusoff BA, Williams DH, Weissman MM, et al. Treatment of secondary depression in schizophrenia. A double blind, placebo controlled trial of amitriptyline added to perphenazine. *Arch Gen Psychiatry.* 1979;36:569–575.
40. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. *Arch Gen Psychiatry.* 1989;46:922–928.
41. Yasui-Furukori N, Kondo T, Mihara K, et al. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. *Psychopharmacology.* 2004;171:223–227.

Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: In vivo evidence of involvement of P-glycoprotein in risperidone disposition

Objective: A recent in vitro study has shown that risperidone is a substrate of P-glycoprotein. The aim of this study was to confirm the effects of verapamil, a P-glycoprotein inhibitor, on the pharmacokinetics of risperidone.
Methods: Two 6-day courses of either 240 mg verapamil daily, an inhibitor of P-glycoprotein, or placebo were administered in a randomized crossover fashion with at least a 4-week washout period. Twelve male volunteers took a single oral 1-mg dose of risperidone on day 6 of both courses. Plasma concentrations of risperidone, 9-hydroxyrisperidone, and prolactin were monitored up to 24 hours after dosing.
Results: Compared with placebo, verapamil treatment significantly increased the peak plasma concentration of risperidone by 1.8-fold and the area under the plasma concentration–time curve (AUC) from 0 to 24 hours of risperidone by 2.0-fold but did not alter the elimination half-life. The AUC from 0 to 24 hours of 9-hydroxyrisperidone, but not other pharmacokinetic parameters, was significantly increased during verapamil treatment. However, the AUC from 0 to 4 hours and the AUC from 0 to 8 hours of prolactin concentrations were not increased by verapamil treatment despite the pharmacokinetic alterations.
Conclusion: This study demonstrated that the bioavailability of risperidone was increased by verapamil, suggesting in vivo involvement of P-glycoprotein in the pharmacokinetics of risperidone. (Clin Pharmacol Ther 2005;78:43-51.)

Taku Nakagami, MD, Norio Yasui-Furukori, MD, PhD, Manabu Saito, MD, Tomonori Tateishi, MD, PhD, and Sunao Kaneo, MD, PhD *Hirosaki, Japan*

Recently, it has become increasingly evident that drug transporters have a pivotal role in the pharmacokinetics of numerous drugs with therapeutic implications.[1-6] Numerous studies have revealed that targeted expression of drug uptake and efflux transport to specific cell membrane domains allows for the efficient directional movement of many drugs in clinical use.[1-6] Transport by adenosine triphosphate–dependent efflux pumps, such as P-glycoprotein, influences the intestinal absorption,[7,8] renal[9,10] or hepatic elimination,[11] and central nervous system concentrations[8] of many drugs.

Risperidone is one of the representative atypical antipsychotic drugs and has potent antagonistic properties for serotonin 5-HT_2 and dopamine D2 receptors.[12,13] This drug is characterized by its effectiveness against both positive and negative symptoms in the treatment of schizophrenia.[14] Furthermore, it produces fewer side effects, including extrapyramidal side effects, than conventional antipsychotic drugs.[15] A recent in vitro study has examined the activity of P-glycoprotein toward 4 atypical and 2 conventional antipsychotics and a proven substrate, verapamil, by their P-glycoprotein adenosine triphosphatase activity, a putative measure of P-glycoprotein affinity.[16] The rank order of the ratio of maximum velocity to Michaelis-Menten constant was as follows: verapamil (2.6) > quetiapine fumarate (INN, quetiapine) (1.7) > risperidone (1.4) > olanza-

From the Departments of Neuropsychiatry and Clinical Pharmacology, Hirosaki University School of Medicine.
This study was supported by grants in aid from the Japanese Ministry of Education, Culture, Sports and Technology (No. 15790612), by a grant from the Pharmacological Research Foundation (Tokyo), by the Hirosaki Research Institute for Neurosciences, and by an advanced medical development cost (B) from the Japanese Ministry of Education, Culture, Sports and Technology and a strategic cost from Hirosaki University.
Received for publication Dec 1, 2004; accepted March 28, 2005.
Reprint requests: Norio Yasui-Furukori, MD, PhD, Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan.
E-mail: *yasufuru@cc.hirosaki-u.ac.jp*
0009-9236/$30.00

doi:10.1016/j.clpt.2005.03.009

pine (0.8) > chlorpromazine (0.7) > haloperidol (0.3). The atypical antipsychotics quetiapine fumarate and risperidone were relatively good P-glycoprotein substrates, although their affinities were not as high as that of verapamil. These results suggest that P-glycoprotein is likely to influence absorption in the small intestine or excretion in the liver or kidney of all atypical antipsychotics to various degrees. However, there are no in vivo data indicating that quetiapine fumarate or risperidone as a substrate of P-glycoprotein is of clinical relevance, although some in vivo data have shown a lack of impact of the multidrug resistance 1 (MDR1) genotype on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone.[17]

Verapamil, a short-term inhibitor of mainly P-glycoprotein, has been used to increase the therapeutic effectiveness of cytotoxic anticancer drugs in cancer chemotherapy.[18] More recently, P-glycoprotein reversal agents including verapamil have been demonstrated to alter the pharmacokinetic properties of coadministered agents in therapeutic areas other than oncology.[19]

The aim of this study was to confirm the effects of verapamil, a transporting inhibitor, on the disposition of risperidone and its active metabolite, 9-hydroxyrisperidone. Prolactin response to risperidone was also examined to clarify the effect of P-glycoprotein activity modulated by verapamil on the pharmacodynamics of risperidone.

METHODS

Subjects

Twelve healthy Japanese male volunteers were enrolled in this study. Their mean age (±SD) was 24.0 ± 2.0 years (range, 20-28 years), and their mean body weight was 64.8 ± 6.2 kg (range, 53-86 kg). The Ethics Committee of Hirosaki University School of Medicine, Hirosaki, Japan, approved the study protocol, and written informed consent was obtained from each participant before any examinations.

Study design

A randomized crossover study design was conducted at intervals of 4 weeks. Two 40-mg tablets of verapamil (Vasolan; Eisai Pharmaceutical, Tokyo, Japan) 3 times daily (at 8 AM, 1 PM, and 6 PM) or matched placebo with 240 mL of tap water was given for 6 days. The volunteers took a single oral 1-mg dose of risperidone at 9 AM on day 6 with 240 mL of tap water. Compliance with taking the test drug was confirmed by pill count. No other medications were taken during the study periods. No meal was allowed until 4 hours after dosing (at 1 AM). The use of alcohol, tea, coffee, and cola was forbidden during the test days.

Sample collections

Blood samples (5 mL each) for determination of risperidone and 9-hydroxyrisperidone and prolactin concentrations were taken into heparinized tubes just before and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after the administration of risperidone. Plasma was separated immediately and kept at −30°C until analysis. At the same time of blood sampling, blood pressure, heart rate, and Udvalg for Klinicke Undersøgelser (UKU) side effects rating scales[20] were monitored. The UKU consisted of 18 items, ie, psychic (concentration difficulties, asthenia, sleepiness, failed memory, and depression), extrapyramidal (dystonia, rigidity, hypokinesia, hyperkinesia, tremor, akinesia, and increased salivation), and autonomic (accommodation disturbances, reduced salivation, constipation, micturition disturbance, orthostatic dizziness, and palpitation) side effects, and was classified from 0 to 3 for each item.

Assay

Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured via the liquid chromatography–tandem mass spectrometry method described by Yasui-Furukori et al.[17] In brief, the extraction procedure was as follows: to 200 μL of plasma sample was added 200 μL of 0.1-mol/L phosphate buffer (pH 7), 50 μL of internal standard solution (R068808; Jansen Research Foundation, Beerse, Belgium), and 100 μL of methanol. Thereafter, 400 μL of 0.1-mol/L Borax (Sigma Coatings, Hasselt, Belgium) was added. The mixture was whirled in a vortex blender and poured over an Extrelut NT 1 (Merck, Boston, Mass) column, which was eluted with 7 mL of ethyl acetate. The eluate was evaporated under a nitrogen stream at 65°C and was redissolved in 100 μL of methanol, which was again evaporated under a nitrogen stream at 65°C. The residues were redissolved in 200 μL of acetonitrile/0.01-mol/L ammonium acetate (50/50, pH 9.0), and 5 μL was injected onto the liquid chromatography–mass spectrometry–mass spectrometry system. The system consisted of API 3000 (Applied Biosystems, Foster City, Calif) and a column (Hypersil BDS C18, 100 × 4.6, 3 μm [Chemco Scientific, Brussels, Belgium]). The mobile phase was gradient ammonium acetate (0.01 mol/L, pH 9.0)–acetonitrile. Among the fragment ions of the compounds, the mass-to-charge ratio (*m/z*) 207.0 for risperidone, *m/z* 191.0 for 9-hydroxyrisperidone, and *m/z* 201.0 for the internal standard were selected for ion monitoring. The lower limit of detection was 0.1 ng/mL for risperidone and 9-hydroxyrisperidone, and the values of

the intra-assay and interassay coefficient of variation were less than 5% at all of the concentrations (0.1-100 ng/mL) of calibration curves for both compounds.

Plasma concentrations of prolactin were quantitated via enzyme immunoassay (IMX Prolactin Dainapack; Dainabot, Tokyo, Japan). The lower limit of detection was 0.6 ng/mL, and the values of the interassay coefficient of variation were 3.7%, 3.5%, and 3.5% at the concentrations of 8, 20, and 40 ng/mL for prolactin, respectively.

Cytochrome P450 2D6 genotypes

For the determination of cytochrome P450 (CYP) 2D6 genotype, deoxyribonucleic acid was isolated from peripheral leukocytes by a guanidium isothiocyanate method. The *CYP2D6*1*, *CYP2D6*3*, and *CYP2D6*4* alleles were identified by allele-specific polymerase chain reaction (PCR) analysis according to Heim and Meyer.[21] A long-PCR analysis was used to detect the *CYP2D6*5* allele.[22] The *CYP2D6*10* allele was identified as the C188T mutation by use of 2-step PCR analysis as described by Johansson et al.[23] The *CYP2D6*14* allele was identified as the G1846T/A mutation by use of 2-step PCR analysis as described by Kubota et al.[24] *CYP2D6*2* does not result in decreased CYP2D6 activity. Therefore *CYP2D6*2* was regarded as the wild-type (wt) allele, together with *CYP2D6*1*.

Date analyses of pharmacokinetics

The peak concentration (C_{max}) and concentration peak time (t_{max}) were obtained directly from the original data. The terminal elimination rate constant (k_e) was determined by log-linear regression of the final data points (4). The apparent elimination half-life of the log-linear phase ($t_{½}$) was calculated as follows: 0.693/k_e. The area under the plasma concentration–time curve (AUC) from 0 to 24 hours [AUC(0-24)] was calculated with use of the linear-linear trapezoidal rule. AUC from time 0 to infinity [AUC(0-∞)] or total AUC was calculated by AUC(0-24) + C_{last}/k_e, where C_{last} was the plasma drug concentration at the last detectable time point.

Statistical analysis

Data are shown as mean ± SD in tables and mean ± SE in figures. Paired *t* test was used for the comparison of the plasma drug concentrations and scores of clinical assessments between 2 phases (ie, placebo and verapamil). The comparison of t_{max} was performed by use of the Wilcoxon signed-sample test. One-way ANOVA was used to compare CYP2D6 genotype effect on this interaction. A *P* value of .05 or less was regarded as significant. Geometric mean ratios to corresponding values in the placebo phase with 95% confidence intervals (CIs) were used for detection of significant differences. When the 95% CI did not cross 1.0, the result was also regarded as significant. SPSS 12.0J for Windows (SPSS Japan, Tokyo, Japan) was used for these statistical analyses.

RESULTS

The subjects had the following CYP2D6 genotypes: wt/wt in 3 subjects, **10*/wt in 5, **10/*10* in 1, and **5/*10* in 3. No subjects regarded as poor metabolizers were included. The subjects were divided into 3 groups according to the number of mutated alleles: there were no mutated alleles in 2 subjects, 1 mutated allele in 6, and 2 mutated alleles in 4.

Pharmacokinetics

Plasma drug concentration–time curves during both placebo and verapamil treatments are shown in Fig 1, and their pharmacokinetic parameters are summarized in Table I. The C_{max} of risperidone during verapamil treatment was higher than the corresponding value during the placebo phase by 1.76-fold (95% CI, 1.36- to 2.49-fold). The AUC(0-24) of risperidone during verapamil treatment was higher than during placebo by 1.97-fold (95% CI, 1.37- to 3.01-fold). The total AUC of risperidone during verapamil treatment was higher than during placebo by 1.82-fold (95% CI, 1.24- to 2.82-fold). No change was found in t_{max} (0.88-fold [95% CI, 0.60- to 1.52-fold]) or elimination $t_{1/2}$ (0.92-fold [95% CI, 0.78- to 1.19-fold]) of risperidone.

The geometric mean ratio of C_{max} of 9-hydroxyrisperidone was 1.14 (95% CI, 0.99- to 1.36-fold). The geometric mean ratios of AUC(0-24) and total AUC of 9-hydroxyrisperidone were 1.46-fold (95% CI, 1.00- to 2.24-fold) and 1.50-fold (95% CI, 0.76- to 2.89-fold), respectively. No differences in t_{max} (1.07-fold [95% CI, 0.78- to 1.68-fold]) or elimination $t_{1/2}$ (1.15-fold [95% CI, 0.83- to 1.74-fold]) were found.

The C_{max} values of active moiety (risperidone plus 9-hydroxyrisperidone) (1.34-fold [95% CI, 1.19- to 1.55-fold]) were increased during verapamil treatment. The AUC(0-24) (1.39-fold [95% CI, 1.28- to 1.52-fold]) and total AUC (1.38-fold [95% CI, 1.24- to 1.57-fold]) of active moiety during verapamil treatment were significantly higher than the corresponding value before the coadministration.

The AUC ratio of risperidone to 9-hydroxyrisperidone was not altered (1.21-fold [95% CI, 0.78- to 2.31-fold]). The mean magnitude (±SD) of the risperidone-verapamil interaction was 3.2 ± 2.5–fold in subjects with no mutated allele, 1.7 ± 0.3–fold in subjects with 1 mutated allele,



Fig 1. Mean plasma concentration–time curves of risperidone, 9-hydroxyrisperidone, and active moiety after single oral 1-mg dose of risperidone. *Open circles* indicate placebo and *solid circles* indicate verapamil. *Error bars* indicate SE.

Table I. Pharmacokinetic parameters of drug concentrations after single oral 1-mg dose of risperidone during placebo and verapamil treatments

	Placebo	*Verapamil*	*Significance*
Risperidone			
C_{max} (ng/mL)	5.9 ± 3.1	10.0 ± 4.2	$P < .001$
t_{max} (h)	2.0 (0.75-3.0)	1.0 (1.0-6.0)	NS
AUC(0-24) (ng · h/mL)	32.6 ± 29	56.2 ± 37.6	$P < .001$
Total AUC (ng · h/mL)	39.4 ± 34.9	62.8 ± 43.1	$P < .001$
$t_{1/2}$ (h)	3.9 ± 1.9	3.6 ± 2.2	NS
9-Hydroxyrisperidone			
C_{max} (ng/mL)	5.4 ± 2.4	6.2 ± 2.9	$P < .01$
t_{max} (h)	4.0 (1.0-12.0)	4.0 (1.0-12.0)	NS
AUC(0-24) (ng · h/mL)	73.9 ± 31.7	94.8 ± 37.3	$P < .01$
Total AUC (ng · h/mL)	105.9 ± 40.9	136.8 ± 46.3	$P < .05$
$t_{1/2}$ (h)	13.4 ± 10.1	13.4 ± 9.3	NS
Active moiety			
C_{max} (ng/mL)	10.2 ± 2.3	13.9 ± 4.1	$P < .01$
AUC(0-24) (ng · h/mL)	110.0 ± 22.0	154.22 ± 39.3	$P < .001$
Total AUC (ng · h/mL)	137.2 ± 28.6	194.29 ± 60.0	$P < .001$

Data are shown as mean ± SD, except for t_{max}, which is shown as median and range.
C_{max}, Peak concentration; t_{max}, time to peak concentration in plasma; NS, not significant; AUC(0-24), area under plasma concentration–time curve from 0 to 24 hours; Total AUC, area under plasma concentration–time curve from time 0 to infinity; $t_{1/2}$, elimination half-life.

and 2.0 ± 1.3–fold in subjects with 2 mutated alleles (*df* = 2,9; F = 1.72; *P* = not significant).

Pharmacodynamics

UKU score–time curves and plasma concentration–time curves of prolactin and during both treatments are shown in Figs 2 and 3, and the pharmacokinetic parameters of prolactin are summarized in Table II. Although there were mild side effects (chest pain) in 1 subject, no clinically significant adverse events were reported during days 1 to 5. Mild to moderate psychic side effects (eg, concentration difficulty, latency, and sleepiness)

were observed from 2 to 12 hours after the risperidone administration in almost all subjects. There was no change in the peak UKU score (4.7 ± 2.3 versus 3.2 ± 1.6, P = not significant; 0.67-fold [95% CI, 0.52- to 1.15-fold]). The area under the UKU score–time curve during placebo was significantly higher than that during verapamil (29.7 ± 21.3 versus 14.4 ± 10.8, $P < .05$). However, the geometric mean ratio of the area under the UKU score–time curve was 0.53 (95% CI, −0.29- to 3.05-fold).

The geometric mean ratio of C_{max} of prolactin between placebo and verapamil treatments was 1.08 (95% CI, 0.96- to 1.27-fold). Those of AUC(0-4), AUC(0-8), AUC(0-24), and incremental AUC of prolactin were 1.15-fold (95% CI, 1.01- to 1.26-fold), 1.12-fold (95% CI, 1.02- to 1.25-fold), 1.24-fold (95% CI, 1.12- to 1.39-fold), and 1.20-fold (95% CI, 0.73- to 2.23-fold), respectively.

DISCUSSION

The results of this study showed a significant increase in the plasma concentration of risperidone (C_{max} and AUC) during verapamil treatment. These findings imply that verapamil increases the bioavailability of risperidone or decreases the total clearance of risperidone. However, because verapamil did not alter the elimination $t_{1/2}$ of risperidone in this study, it appears that only the bioavailability of risperidone was increased by verapamil, which might be attributed to increased absorption of risperidone in the small intestine or inhibition of extraction to bile in the liver. Our recent study showed that verapamil increased the bioavailability of fexofenadine,[25] probably through P-glycoprotein inhibition. Because a recent jejunal single-pass perfusion study suggested that verapamil treatment did not alter the permeability of fexofenadine,[26] it is more likely that the interaction between verapamil and risperidone occurs in the first-pass liver extraction process.

Our previous report showed a lack of effects of major polymorphisms of the *MDR1* gene on steady-state plasma drug concentrations in 85 schizophrenic patients receiving 3 mg risperidone twice daily.[17] When *MDR1* variants alter the activity of P-glycoprotein in the small intestine, which limits oral bioavailability, the peak concentration of risperidone may differ between *MDR1* genotypes. However, plasma concentrations of risperidone were monitored at 12 hours after dosing in the present study. Therefore any difference in the peak plasma concentration of risperidone caused by *MDR1* variants was offset by large interindividual variability in risperidone metabolism during the elimination phase.



Fig 2. Mean Udvalg for Klinicke Undersøgelser (UKU) side effect rating scale score–time curves after single oral 1-mg dose of risperidone. *Open circles* indicate placebo and *solid circles* indicate verapamil. *Error bars* indicate SE.



Fig 3. Mean plasma concentration–time curves of prolactin after single oral 1-mg dose of risperidone. *Open circles* indicate placebo and *solid circles* indicate verapamil. *Error bars* indicate SE.

Verapamil is regarded as an inhibitor of CYP3A, as well as P-glycoprotein, on the basis of several in vitro and in vivo investigations.[27-29] Fang et al[30] demonstrated that CYP3A is a major enzyme catalyzing 9-hydroxylation of risperidone. On the basis of these facts, therefore, it is possible that significant interaction between these drugs

Table II. Pharmacokinetic parameters of prolactin concentration and AUC ratios of prolactin to drug concentration after single oral 1-mg dose of risperidone during placebo and verapamil treatments

	Placebo	*Verapamil*	*Significance*
C_{max} (ng/mL)	84.4 ± 21.8	95.6 ± 39.1	NS
AUC(0-4) (ng · h/mL)	15.5 ± 10.4	26.0 ± 13.3	NS
AUC(0-8) (ng · h/mL)	25.6 ± 18.8	42.3 ± 24.4	NS

Data are shown as mean ± SD.
AUC(0-4), Area under plasma concentration–time curve from 0 to 4 hours; AUC(0-8), area under plasma concentration–time curve from 0 to 8 hours.

occurs as a result of inhibition of CYP3A. Our previous in vitro study showed that intrinsic clearance for (+)-9-hydroxylation of risperidone catalyzed by CYP2D6 was 25.2 ± 12.2 $\mu L \cdot min^{-1} \cdot mg^{-1}$, whereas that for (+)- and (−)-9-hydroxylation of risperidone catalyzed by CYP3A was 6.65 ± 2.15 $\mu L \cdot min^{-1} \cdot mg^{-1}$ and 3.89 ± 1.74 $\mu L \cdot min^{-1} \cdot mg^{-1}$, respectively, suggesting that CYP2D6 was more predominant than CYP3A in clinically relevant concentrations of risperidone.[31] In fact, there was no difference in the elimination half-life of risperidone, which is well influenced by drug metabolism. In addition, although alternative contribution of CYP3A to risperidone metabolism in subjects with low CYP2D6 activity is assumed, the magnitude of this interaction in subjects with 2 mutated alleles for CYP2D6 was not different from that in other genotype groups. Thus it seems that the drug interaction did not lead to an inhibitory effect of verapamil on hepatic CYP3A. However, the possibility that inhibition of CYP3A in the small intestine during verapamil treatment caused the increased absorption of risperidone cannot be excluded.

Also, verapamil is a nonspecific inhibitor of several membrane transport proteins, including P-glycoprotein and organic anion transporting polypeptide (OATP) A.[32] In contrast, there are no data indicating that OATPs have any role in risperidone penetrating membrane. In the current study, therefore, the possibility that verapamil alters risperidone pharmacokinetics through an inhibition of OATPs cannot be excluded.

The metabolite 9-hydroxyrisperidone is mainly removed through renal excretion,[33] whereas P-glycoprotein exists in the renal proximal tubule.[34] Consequently, it is possible that the plasma concentration of 9-hydroxyrisperidone depends on P-glycoprotein activity, and we assumed that the difference in 9-hydroxyrisperidone concentration would be larger. However, the pharmacokinetic parameters of 9-hydroxyrisperidone were not influenced by verapamil treatment as much as risperidone. This finding suggests either that 9-hydroxyrisperidone is not such a specific substrate of P-glycoprotein or that renal excretion of the compound may be mediated by other transporters. In addition, the formation of 9-hydroxyrisperidone is mainly catalyzed by CYP2D6,[31] but plasma concentrations of 9-hydroxyrisperidone are not dependent CYP2D6 activity.[35-38] Further study is required to clarify the disposition of 9-hydroxyrisperidone.

Likewise, verapamil was associated with the active moiety concentration. This is a reasonable finding in light of the alteration of plasma concentrations of risperidone. Apart from steady state, the active moiety concentration is influenced by both plasma concentrations of risperidone and 9-hydroxyrisperidone because the plasma concentration of 9-hydroxyrisperidone was similar to that of risperidone after a single oral dose of risperidone.[39] From this pharmacokinetic point of view, we concluded that P-glycoprotein modulation has potential clinical implications based on changes in peak plasma concentrations.

The major physiologic role of P-glycoprotein is to serve as a barrier to entry and as an efflux mechanism for xenobiotics and cellular metabolites.[40] Not only may P-glycoprotein limit intestinal drug absorption to constrain oral drug bioavailability, but the rate of P-glycoprotein efflux transport can also mediate brain penetration of lipophilic drugs.[41,42] This is based on several kinetic studies showing large differences in brain concentration between the knockout animal [*mrd1a* (−/−) and *mrd1a/1b* (−/−) mice] and normal animal [*mrd1a* (+/+) and *mrd1a/1b* (+/+) mice].[43] Therefore interindividual variability of P-glycoprotein function in the brain contributes to this variability of clinical response to neuropsychiatric agents.

A few studies have suggested that inhibition of P-glycoprotein in the central nervous system affects pharmacodynamic alteration. Loperamide produced no respiratory depression when administered alone, but respiratory depression occurred when loperamide (16 mg) was given with quinidine at a dose of 600 mg.[44] These changes were not explained by increased plasma loperamide concentrations. This study demonstrates the potentially important drug interactions that occur by inhibition of P-glycoprotein.

Several positron emission tomography studies suggested that risperidone disposition in plasma is not associated with that in the brain.[45,46] Because the inhibition of P-glycoprotein activity during verapamil treatment probably leads to elevation of risperidone concentrations in the brain, we assumed that the prolactin concentration or prolactin concentration normalized by plasma concentration should be increased during verapamil treatment. In addition, several animal studies showing that the brain concentration of P-glycoprotein substrates increased after verapamil treatment support our hypothesis, although these studies used experimental doses of verapamil.[47,48]

Contrary to our expectation, the prolactin concentration was not affected during verapamil treatment. We do not have a clear explanation for this finding. A previous study demonstrated that verapamil infusion decreased the prolactin concentration in patients with hyperprolactinemia induced by sulpiride, which is a dopamine D_2 antagonist, but increased the prolactin concentration in patients with hyperprolactinemia induced by prolactinoma.[49] Further studies with respect to the pharmacodynamic effect of verapamil are required.

The area under the UKU score–time curve during placebo was significantly higher than that during verapamil treatment, although the active moiety concentration was increased during verapamil treatment in this study. The possibility that this finding is ascribable to more sequence effects in the placebo-verapamil group than that in the verapamil-placebo group cannot be excluded entirely.

In conclusion, this study showed that verapamil increased risperidone exposure, probably because of an increase in bioavailability through P-glycoprotein inhibition. Change in the regulation of transporters such as P-glycoprotein, though not simple, may lead to significant alteration of risperidone pharmacokinetics.

We thank Dr Ronald De Vries (Pharmacokinetics, Janssen Research Foundation, Beerse, Belgium) for her expertise in measuring the risperidone and 9-hydroxyrisperidone levels.

None of the authors or their institutes has conflicts of interest.

References

1. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31:469-97.
2. Kim RB. Transporters and xenobiotic disposition. Toxicology 2002;181-2:291-7.
3. Hochman JH, Yamazaki M, Ohe T, Lin JH. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 2002;3:257-73.
4. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
5. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003;33(Suppl 2):6-9.
6. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 2004; 10:RA5-14.
7. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000;12:3-12.
8. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000;38:69-74.
9. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000; 58:944-58.
10. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004;44:137-66.
11. Hooiveld GJ, van Montfoort JE, Meijer DK, Muller M. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur J Pharm Sci 2001;12:525-43.
12. Jansen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-93.
13. Leysen JE, Gommeren W, Eeens A, de Chaffoy de Courdells D, Stoof JC, et al. Biochemical profiles of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;244:685-93.
14. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chromic schizophrenia inpatians: multicenter double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
15. Chouinard G, Jones B, Remington G, Bloom D, Addington D, Macewan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 1993;13:25-40.
16. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002;71:163-9.
17. Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004;57:569-75.
18. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, et al. Verapamil increases

the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000;11:1471-6.
19. Molento MB, Lifschitz A, Sallovitz J, Lanusse C, Prichard R. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol Res 2004;92:121-7.
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
21. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
22. Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
23. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
24. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;50:31-4.
25. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine and probenecid on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005;77:17-23.
26. Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernas H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin Pharmacol Ther 2003;74:423-36.
27. Zhao XJ, Ishizaki T. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet 1999;24:272-8.
28. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000;28:125-30.
29. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-66.
30. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999;359:147-51.
31. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001;29:1263-8.
32. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-71.
33. Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995;122:223-9.
34. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001;21:778-96.
35. Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999;147:300-5.
36. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001;57:671-5.
37. Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003;43:122-7.
38. Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 2003;25:287-93.
39. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
40. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-8.
41. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
42. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:25-31.

43. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999;96:3900-5.
44. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68:231-7.
45. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7:317-21.
46. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 2004;7:19-26.
47. Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42:1231-40.
48. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002 ;327: 173-6.
49. Knoepfelmacher M, Villares SM, Nicolau W, Germek OO, Lerario AC, Wajchenberg BL, et al. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia. Horm Metab Res 1994;26:481-5.

Available online at www.sciencedirect.com
SCIENCE DIRECT®
Journal of Pharmaceutical and Biomedical Analysis 37 (2005) 121–125
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
www.elsevier.com/locate/jpba

Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid–liquid extraction and column-switching high-performance liquid chromatography

Norio Yasui-Furukori[a,*], Yoshimasa Inoue[b], Sunao Kaneko[a], Koichi Otani[c]

[a] *Department of Neuropsychiatry, Hirosaki University School of Medicine, Zaifu cho 5, Hirosaki 0368562, Japan*
[b] *Pharmaceutical Technology Division, Mitsubishi Pharma, Fukuoka, Japan*
[c] *Department of Neuropsychiaty, Yamagata University School of Medicine, Yamagata, Japan*

Received 20 July 2004; received in revised form 23 September 2004; accepted 25 September 2004
Available online 10 November 2004

Abstract

This study describes a new simultaneous determination of fluvoxamine and fluvoxamino acid by automated column-switching high-performance liquid chromatography. The test compounds were extracted from 1.5 ml of plasma using chloroform–toluene (15:85, v/v), and the extract was injected into a hydrophilic metaacrylate polymer column for clean-up and a C18 analytical column for separation. The mobile phase for separation consisted of phosphate buffer (0.02 M, pH 4.6), acetonitrile and perchloric acid (60%) (62.4:37.5:0.1, v/v/v) and was delivered at a flow rate of 0.6 ml/min. The peak was detected using a UV detector set at 254 nm. The method was validated for the concentration range 0.8–153.6 ng/ml for fluvoxamine and 0.6–115.2 ng/ml for fluvoxamino acid, and their good linearity ($r > 0.998$) were confirmed. Intra-day coefficient variations (CVs) for fluvoxamine and fluvoxamino acid were less than 6.6 and 6.0%, respectively. Inter-day CVs for corresponding compounds were 6.3 and 6.5%, respectively. Relative errors ranged from −18 to 9% and mean recoveries were 96–100%. The limit of quantification was 1.2 and 0.9 ng/ml for fluvoxamine and fluvoxamino acid, respectively. This method shows successful application for pharmacokinetic studies and therapeutic drug monitoring.

Keywords: Fluvoxamine; Fluvoxamino acid; HPLC; Column-switching

1. Introduction

Fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, shows similar therapeutic efficacy to tricyclic antidepressants, but fewer anticholinergic and cardiovascular side effects [1]. Nausea is the most common side effect of fluvoxamine [1]. Fluvoxamine undergoes extensive metabolism, and the major metabolite in human urine is fluvoxamino acid [2]. A clinical trial showed that the steady-state plasma concentration of fluvoxamino acid was correlated with the therapeutic outcome [3]. It appears that fluvoxamino acid as well as fluvoxamine contributes to the antidepressant effect during fluvoxamine treatment, and the combined steady-state plasma concentration correlates well with the therapeutic outcome. On the other hand, the fluvoxamino acid/fluvoxamine ratio was significantly different between CYP2D6 genotypes [4]. From not only a clinical point of view but also a pharmacokinetic point of view, therefore, monitoring of both fluvoxamine and fluvoxamino acid is clinically relevant.

Several HPLC methods with ultraviolet detection for the determination of fluvoxamine concentration have been widely reported [5–18]. Although simultaneous determination of antidepressants including fluvoxamine has been reported [16], potential active metabolite has not been included in these studies. Of these reports, only a report by Ohkubo et al. [16] described determination of steady-state plasma concentration of fluvoxamine and fluvoxamino acid in de-

* Corresponding author. Tel.: +81 172 39 5066; fax: +81 172 39 5067.
E-mail address: yasufuru@cc.hirosaki-u.ac.jp (N. Yasui-Furukori).

0731-7085/$ – see front matter © 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.jpba.2004.09.037



Fig. 1. Chemical structure analogues of fluvoxamine, fluvoxamino acid and cisapride.

pressed patients. However, because preclinical pharmacokinetic data showed C_{max} of 10–15 ng/ml after a single oral dose (50 mg) of fluvoxamine [19], the quantification limits (10 ng/ml) of both compounds in their report [16] are too high to obtain pharmacokinetic parameters of these compounds. In the present study, therefore, we describe an automated column-switching HPLC with ultraviolet detection for determination of fluvoxamine and fluvoxamino acid in plasma using a simple liquid–liquid extraction. The sensitive system allows measurement of plasma concentrations of fluvoxamine and fluvoxamino acid up to 36 and 12 h, respectively, after an oral administration of 50 mg fluvoxamine in pharmacokinetic study.

2. Experimental

2.1. Chemicals

Fluvoxamine and fluvoxamino acid (Fig. 1) were synthesized by Wako Pure Chemical Industries (Osaka, Japan). The structures of these compounds were confirmed using NMR spectra and FAB–MS. The purity of these materials was more than 99.5%. Cisapride as internal standard (IS) (Fig. 1) was kindly provided by Yoshitomi Pharmaceutical (Osaka, Japan). Potassium phosphate monobasic, acetonitrile, perchloric acid, toluene and chloroform were purchased from Wako Pure Chemical Industries (Osaka, Japan). Water was deionized and purified using a Milli-Q system (Millipore, Bedford, MA, USA).

2.2. Drug solutions

Stock solutions of fluvoxamine, fluvoxamino acid and IS for generating standard curves were prepared by dissolving an appropriate amount of each compound in methanol to yield concentrations of 76.8, 57.6 and 1000 μg/ml, respectively. High-concentration working standard solutions of fluvoxamine (768 ng/ml), fluvoxamino acid (576 ng/ml) and IS (10 μg/ml) were obtained by 100 times dilution of each stock solution with purified water. Low-concentration working standard solution of fluvoxamine (96 ng/ml) and fluvoxamino acid (72 ng/ml) were obtained by further diluting the high-concentration working standard solution eight times with purified water. Stock solutions were stable at 4 °C for at least 3 months. Drug-free plasma from healthy donors was used for validation studies. Calibration curves were prepared by spiking 12.5, 25, 50 μl of low-concentration working standard solutions and 12.5, 25, 50, 100, 150, 200, 300 μl of high-concentration working standard solutions in 1.5 ml of blank plasma (final volume) to yield the following final concentrations: 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 51.2, 76.8, 102.4 and 153.6 ng/ml for fluvoxamine and 0.6, 1.2, 2.4, 4.8, 9.6, 19.2, 38.4, 57.6, 76.8 and 115.2 ng/ml for fluvoxamino acid. Standard curves were prepared daily and constructed by linear regression analysis of the compounds/internal standard peak-height ratio versus the respective concentration of fluvoxamine and fluvoxamino acid. Stock solution of each compound was separately prepared for quality controls in the same manner as for standard curves. Working plasma solutions were obtained by dilution of new stock solutions 1000 times (360 μg/ml for fluvoxamine and 270 μg/ml for fluvoxamino acid) with blank plasma to yield 360 ng/ml for fluvoxamine and 270 ng/ml for fluvoxamino acid. Quality control samples were obtained by spiking 5–400 μl of working plasma solutions in 1.5 ml of blank plasma (final volume) to yield the final concentrations range of 1.2, 24 and 96 ng/ml for fluvoxamine and 0.9, 18 and 72 ng/ml for fluvoxamino acid, and kept at −20 °C until analysis. All standard curves were checked using these quality control samples.

2.3. Sample collections

A tablet containing 50 mg of fluvoxamine (Luvox®, Fujisawa Pharmaceutical, Osaka, Japan) was orally administered to each of 10 healthy volunteers. Their mean (range) age was 31 years (25–36 years) and body weight was 64 kg (54–85 kg). Blood samples were obtained before and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after the dosing. Blood samples were collected in heparinized tubes and centrifuged immediately at 2500 × *g* for 10 min. The plasma was stored at −20 °C until analysis. The study protocol was approved by Ethical Committee of Hirosaki University School of Medicine and Ethical Committee of Yamagata University School of Medicine and a written informed consent was given from each subject.

2.4. Apparatus

The column-switching HPLC system consisted of two Shimadzu LC-10AT high-pressure pumps (for eluent A and B), a Shimadzu CTO-10A column oven and a Shimadzu Work station CLASS-VP chromatography integrator (Kyoto, Japan), a Shimadzu SPD-10AVP (Kyoto, Japan), a Tosoh multiple autovalve PT-8000, and a Tosoh autosampler AS-8020 (500 μL injection volume) (Tokyo, Japan). A TSK gel

PW precolumn (a hydrophilic metaacrylate polymer column) for sample clean-up (column I; 35 mm × 4.6 mm ID, particle size 10 μm; Tosoh, Tokyo, Japan) and a C18 STR ODS-II column as an analytical column (column II; 150 mm × 4.6 mm ID, particle size 5 μm; Shinwa Chemical Industry, Kyoto, Japan) were used.

2.5. Extraction procedure

IS (cisapride) 80 μL of 10 μg/ml, 1.0 ml NaOH (0.25 M) were added to 1.5 ml of plasma. The tubes were vortex-mixed for 10 s and 5 ml of toluene–chloroform (85:15, v/v) was added as extraction solvent. After 10 min of shaking, the mixture was centrifuged at 1700 × *g* for 10 min at 4 °C, and the organic phase was evaporated in vacuo at 45 °C to dryness (TAITEC VC-960, Shimadzu, Kyoto, Japan). The residue was dissolved with 750 μL of eluent A and used as an extract.

2.6. Chromatographic condition

Column-switching chromatographic condition was set based on our previous report [20]. A 0.5 ml portion of the extract was automatically injected into the HPLC system. Column-switching time schedule was set based on retention time of fluvoxamino acid in column I (about 12 min), retention time of achievement of maximal recovery of fluvoxamine from column I to column II (about 17 min) and retention time of appearance of interference peaks (about 20 min). From 0 to 11.5 min after the sample injection, fluvoxamine, fluvoxamino acid and IS were separated from the interfering substances present in the extract on column I with a mobile phase (eluent A) of phosphate buffer (0.02 M, pH 4.6), acetonitrile and perchloric acid (60%) (92.4:7.5:0.1, v/v/v). Between 11.5 and 18.0 min after the injection, two analytes and IS retained on column I were eluted with a mobile phase (eluent B) of phosphate buffer (0.02 M, pH 4.6), acetonitrile and perchloric acid (60%) (62.4:37.5:0.1, v/v/v), and effluent from column I was switched to column II. Then fluvoxamine and fluvoxamino acid were separated on column II by eluting with eluent B (between 18.0 and 35.0 min). The flow rates of eluents A and B were 1.2 and 0.6 mL/min, respectively. The temperatures of column I and II were about 25 (room temperatures) and 30 °C, respectively. The peak was detected using a UV detector set at 254 nm. The peak area was used for the quantification of these two compounds.

3. Results and discussion

3.1. Chromatography

Effects of constitution ratio of perchloric acid (0, 0.1, 0.25 and 1.0%) in mobile phase on peak separation of fluvoxamine, fluvoxamino acid and IS were investigated, and 0.1% perchloric acid obtained optimal separation of these compounds.

Table 1
Extraction recovery of analytes from plasma (n =6)

Analyte	Concentration added (ng/mL)	Recovery (%)	CV (%)
Fluvoxamine	1.2	94.8	0.77
	24.0	94.8	0.66
	96.0	94.9	0.71
Fluvoxamino acid	0.9	96.4	0.91
	18.0	96.7	0.90
	72.0	96.4	0.64

A mobile phase with the same pH was adjusted with phospholic acid as with 0.1% perchloric acid did not lead to separation of any these compounds, suggesting a specific effect of perchloric acid but not pH on this method. The chromatogram of an extracted blank plasma sample is shown in Fig. 2A. A representative chromatogram of an extracted blank plasma sample spiked with working aqueous solution containing fluvoxamine and fluvoxamino acid and cisapride (internal standard) is shown in Fig. 2B (2.4 and 1.6 ng/ml, respectively) and C (96 and 72 ng/ml, respectively). The chromatograms of extracted plasma samples obtained from a patient receiving fluvoxamine 100 mg/day did not show interference peaks (Fig. 2D). All compounds were well separated from each other and from the front of the solvent peaks. Plasma concentrations were 41.7 ng/ml for fluvoxamine and 44.8 ng/ml for fluvoxamino acid.

3.2. Recovery and linearity

Absolute recovery from plasma was calculated by comparing the peak areas of pure standards prepared in purified water, and injected directly into the analytical column with those of extracted plasma samples containing the same amount of the test compound (n = 6 each). Recoveries and their CV values were determined at three different concentrations ranging from 1.2 to 96 ng/ml for fluvoxamine and from 0.9 to 72 ng/ml for fluvoxamino acid. Recoveries and their CV values were 94–96% with less than 1% for both compounds (Table 1). Calibration curves were linear over the concentrations range from 0.8 to 153.6 ng/ml (r > 0.998) for fluvoxamine and from 0.6 to 115.2 ng/ml for fluvoxamino acid (r > 0.999).

3.3. Sensitivity

Chloroform, toluene, *n*-hexane, heptane, isopropylether, diethylether and ethyl acetate and their combination were investigated. The combination of toluene–chloroform (85:15, v/v) was the highest sensitivity among these organic solvents because of flat baseline. The limit of detection was defined as analyte responses that were at least three times the response compared to blank response. The limits of detection of fluvoxamine and fluvoxamino acid were 0.4 and 0.3 ng/ml, respectively. The lowest standard on the calibration curve was defined as the limit of quantification as analyte peaks by which both compounds in blank plasma were identifiable,



Fig. 2. Representative chromatogram of extracts of blank plasma (A) and extracts of plasma spiked with 2.4 ng/ml for fluvoxamine and 1.6 ng/ml for fluvoxamino acid (B) and 96 ng/ml for fluvoxamine and 72 ng/ml for fluvoxamino acid (C) and plasma from a patient (D). The peak 1 corresponds with fluvoxamino acid; peak 2 with cisapride; peak 3 with fluvoxamine.

discrete and reproducible with a precision of 20% and accuracy of 80–125%. The limits of quantification were 1.2 ng/ml for fluvoxamine and 0.9 ng/ml for fluvoxamino acid.

3.4. Precision and accuracy

Intra- and inter-day precision and accuracy were evaluated by assaying quality controls with three different concentrations of two compounds. Intra- and inter-day precisions were assessed by analyzing six quality control samples at each concentration on the same day and by analyzing a quality control for 6 days, respectively. These extracts underwent the same column-switching procedure. Intra-day coefficient variations (CVs) for fluvoxamine and fluvoxamino acid were less than 6.6 and 6.0%, respectively. Inter-day CVs for corresponding compounds were 6.3 and 6.5%, respectively (Table 2). Accuracy was expressed as mean percent error (relative error) [(measured plasma concentration − spiked concentration in plasma)/spiked concentration in plasma] × 100 (%) of each quality control plasma sample, while precision was quantitated by calculating intra- and inter CV values.

Table 2
Precision (CV) and accuracy (relative error) for determination of analytes in spiked plasma ($n = 6$)

Analyte	Concentration added (ng/mL)	Intra-day		Inter-day	
		CV (%)	Relative error (%)	CV (%)	Relative error (%)
Fluvoxamine	1.2	6.6	−5.8	6.3	−10.0
	24.0	2.1	−3.8	3.7	−5.1
	96.0	0.8	−1.3	1.0	−2.3
Fluvoxamino acid	0.9	6.0	−7.8	6.5	−10.9
	18.0	2.1	−5.6	2.8	−5.5
	72.0	1.1	−1.3	1.2	−2.4

3.5. Drug concentrations in human plasma

Fig. 3 shows the mean plasma concentration versus time curves of fluvoxamine and fluvoxamino acid after an oral administration of fluvoxamine (50 mg) in 10 subjects. The pharmacokinetic parameters of fluvoxamine and fluvoxamino acid are summarized in Table 3.



Fig. 3. Mean plasma concentration–time curves of fluvoxamine and fluvoxamino acid from 0.5 to 36 h in 10 healthy volunteers after a single-oral dose of fluvoxamine 50 mg. Error bars indicate standard deviation.

Table 3
Pharmacokinetic parameters of fluvoxamine and fluvoxamino acid after a oral 50 mg dose of fluvoxamine in 10 healthy volunteers

Parameters	Mean ± S.D.
Fluvoxamine	
C_{max} (ng/mL)	10.2 ± 2.7
T_{max} (h)	4.5 ± 1.0
$T_{1/2}$ (h)	14.1 ± 3.0
AUC(0–36) (ng h/mL)	131 ± 44
AUC(0–∞) (ng h/mL)	158 ± 64
Fluvoxamino acid	
C_{max} (ng/mL)	2.9 ± 0.8
T_{max} (h)	4.0 ± 0.8
AUC(0–12) (ng h/mL)	21.1 ± 5.9

AUC, area under plasma concentration–time curve; C_{max}, peak concentration; T_{max}, time to C_{max}; $T_{1/2}$, elimination half-life.

The sensitivity in the present simple HPLC method was superior to a previous method using HPLC analysis [16], enabling the monitoring of plasma concentrations of fluvoxamine up to 36 h and fluvoxamino acid up to 12 h after an administration of fluvoxamine 50 mg in all volunteers. Consequently, precise pharmacokinetic parameters were obtained from plasma concentration of fluvoxamine from 12 to 36 h after administration in elimination phase. These results can apply to clinical pharmacokinetic studies in patients receiving fluvoxamine treatment.

4. Conclusion

The new HPLC procedure described for simultaneous determination of fluvoxamine and fluvoxamino acid is suitable for routine analysis even though it is a little time consuming. Satisfactory validation data were achieved for linearity, precision and recovery. The limit of quantification obtained allows measurement of not only therapeutic concentration of fluvoxamine but also pharmacokinetic study using healthy volunteers.

References

[1] M.I. Wilde, G.L. Plosker, P. Benfield, Drugs 46 (1993) 895–924.
[2] H. Overmars, P.M. Scherpenisse, L.C. Post, Eur. J. Drug Metab. Pharmacokinet. 8 (1983) 269–280.
[3] G. Gerstenberg, T. Aoshima, T. Fukasawa, K. Yoshida, H. Takahashi, H. Higuchi, Y. Murata, R. Shimoyama, T. Ohkubo, T. Shimizu, K. Otani, Psychopharmacology 167 (2003) 443–448.
[4] G. Gerstenberg, T. Aoshima, T. Fukasawa, K. Yoshida, H. Takahashi, H. Higuchi, Y. Murata, R. Shimoyama, T. Ohkubo, T. Shimizu, K. Otani, Ther. Drug Monit. 25 (2003) 463–468.
[5] G.J. de Jong, J. Chromatogr. 183 (1880) 203–211.
[6] J. Pommery, M. Lhermitte, Biomed. Chromatogr. 3 (1989) 177–179.
[7] V. Van der Meersch-Mougeot, B. Diquet, J. Chromatogr. 567 (1991) 441–449.
[8] R.H. Pullen, A.A. Fatmi, J. Chromatogr. 574 (1992) 101–107.
[9] S. Hartter, H. Wetzel, C. Hiemke, Clin. Chem. 38 (1992) 2082–2086.
[10] S.H. Wong, H.R. Kranzler, S. DellaFera, R. Fernandes, Biomed. Chromatogr. 8 (1994) 278–282.
[11] L. Palego, D. Marazziti, L. Biondi, G. Giannaccini, N. Sarno, A. Armani, A. Lucacchini, G.B. Cassano, L. Dell'Osso, Ther. Drug Monit. 22 (2000) 190–194.
[12] A. Lucca, G. Gentilini, S. Lopez-Silva, A. Soldarini, Ther. Drug Monit. 22 (2000) 271–276.
[13] R. Skibinski, G. Misztal, Acta Pol. Pharm. 58 (2001) 97–100.
[14] G. Tournel, N. Houdret, V. Hedouin, M. Deveau, D. Gosset, M. Lhermitte, J. Chromatogr. B 761 (2001) 147–158.
[15] L. Labat, M. Deveaux, P. Dallet, J.P. Dubost, J. Chromatogr. B 773 (2002) 17–23.
[16] T. Ohkubo, R. Shimoyama, K. Otani, K. Yoshida, H. Higuchi, T. Shimizu, Anal. Sci. 19 (2003) 859–864.
[17] C. Duverneuil, G.L. de la Grandmaison, P. de Mazancourt, J.C. Alvarez, Ther. Drug Monit. 25 (2003) 565–573.
[18] K. Titier, N. Castaing, E. Scotto-Gomez, F. Pehourcq, N. Moore, M. Molimard, Ther. Drug Monit. 25 (2003) 581–587.
[19] J. van Harten, Clin. Pharmacokinet. 24 (1993) 203–220.
[20] N. Yasui-Furukori, Y. Inoue, T. Tateishi, J. Chromatogr. B 789 (2003) 239–245.